These approaches merge IL-2 with antibodies directed at TAAs (e.g., EpCAM, GD2, CD20, and CEA) or tumor extracellular matrix (ECM) components, enabling selective delivery to the TME and local immune activation [124]. This evidence concerns the gene IL2 and neoplasm.